Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/bjo.2010.195628 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial.
Lancet
January 2025
Francis I Proctor Foundation, University of California San Francisco, San Francisco, CA, USA; Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA; Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA, USA.
Background: Adalimumab is an effective treatment for juvenile idiopathic arthritis-associated uveitis. Data are scarce on the effects of discontinuing adalimumab after control of the disease had been reached. We aimed to assess efficacy and safety of discontinuing treatment in patients with juvenile idiopathic arthritis-associated uveitis.
View Article and Find Full Text PDFClassification of Fibro-osseous Tumors in the Craniofacial Bones using DNA Methylation and Copy Number Alterations.
Mod Pathol
January 2025
Department of Pathology and Medical Biology, University Medical Center Groningen, Groningen, the Netherlands; Department of Pathology, Amsterdam University Medical Center, Amsterdam, the Netherlands. Electronic address:
Fibro-osseous tumors of the craniofacial bones are a heterogeneous group of lesions comprising cemento-osseous dysplasia (COD), cemento-ossifying fibroma (COF), juvenile trabecular ossifying fibroma (JTOF), psammomatoid ossifying fibroma (PsOF), fibrous dysplasia (FD), and low-grade osteosarcoma (LGOS) with overlapping clinicopathological features. However, their clinical behavior and treatment differ significantly, underlining the need for accurate diagnosis. Molecular diagnostic markers exist for subsets of these tumors, including GNAS mutations in FD, SATB2 fusions in PsOF, mutations involving the RAS-MAPK signaling pathway in COD, and MDM2 amplification in LGOS.
View Article and Find Full Text PDFBacteriological Agents and Resistance Profiles in Neonatal Sepsis from a Poorly Regulated Antimicrobial Access Setting: Time for Action.
West Afr J Med
September 2024
Medical Microbiology & Parasitology Department, University of Ilorin, Ilorin, Nigeria. Email:
Background: Neonatal sepsis (NNS) is a known cause of morbidity and mortality especially in developing countries. The global resistance scourge may worsen the management outcomes of NNS. This study aims to determine the current profile of bacteriological agents of NNS, their resistance status and associated mortality in our setting.
View Article and Find Full Text PDFSpectrum of Manifest Strabismus in A Tertiary Eye Care Hospital in Calabar, Nigeria: Demographics, Types and Co-morbidities.
West Afr J Med
September 2024
Department of Ophthalmology, University of Calabar, Calabar, Cross River State, Nigeria.
Background: Strabismus is a potential cause of ocular morbidity.
Objective: The aim of this study was to determine the frequency, types of manifest strabismus and co-morbidities among patients attending a referral paediatric ophthalmology and strabismus clinic in Calabar, Nigeria.
Methods: A retrospective review of case-notes of patients attending the paediatric ophthalmology and strabismus clinic from January 1, 2017 to December 31, 2019 was done.
Assessing the accuracy and usefulness of YouTube videos on small incision lenticule extraction (SMILE) surgery for patients and healthcare professionals.
Lasers Med Sci
January 2025
Department of Ophthalmology, University of Health Sciences, Beyoglu Eye Training and Research Hospital, Istanbul, 34420, Turkey.
To evaluate the quality, usefulness, and reliability of videos about Small Incision Lenticule Extraction (SMILE) surgery on the YouTube platform. On January 19, 2022, a search was performed on YouTube ( www.youtube.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!